Inhibiting acetylation-facilitated STAT3 signaling could reduce the metastasis from NSCLC cells, and hence provide a potentially promising approach for the treatment of NSCLC malignancy in AKR1C1-postive patients. The gene discussed is AKR1C1; the disease is non-small cell lung carcinoma.